Mutations in the CDKN2A (p16(INK4a)) gene in microdissected sporadic primary melanomas

International Journal of Cancer

Volumn 75, Issue 2, 1998, Pages 193-198

  Kumar, Rajiv ^a   Rozell, Barbro Lundh ^b   Louhelainen, Jari ^a   Hemminki, Kari ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GENETICS; CHROMOSOME MICRODISSECTION; DNA POLYMORPHISM; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MELANOMA; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; DISSECTION; GENETIC POLYMORPHISM; GENETICS; MUTATION; SKIN TUMOR;

PROTEIN P16INK4A;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISSECTION; HUMANS; MELANOMA; MUTATION; POLYMORPHISM, GENETIC; SKIN NEOPLASMS;

EID: 0032545582     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980119)75:2<193::AID-IJC5>3.0.CO;2-P     Document Type: Article

References (33)

1. CLARK, W.H., ELDEK, D.E., GUERRY, D., BRAITMAN, L.E., TROCK, B.J., SCHULTZ, D., SYNNESTVEDT, M. and HALPERN, A.C., Model predicting survival in stage-1 melanoma based on tumour progression. J. nat. Cancer Inst., 81, 1893-1904 (1989).
2. COTTON, R.G.H., RODRIGUES, N.R. and CAMPBELL, R.D., Reactivity of cytosine and thymine in single-base-pair mismatches with hydoxylamine and osmium tetroxide and its application to the study of mutations. Proc. nat. Acad. Sci. (Wash.), 85, 4397-4401 (1988).
3. FITZGERALD, M.G., HARKIN, D.P., SILVA-ARRIETA, S., MACDONALD, D.J., LUCCHINA, L.C., UNSAL, H., O'NIELL, E., KOH, J., FINKELSTEIN, D.M., ISSELBACHER, K.J., SOBER, A.J. and HABER, D.A., Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. nat. Acad. Sci. (Wash.), 93, 8541-8545 (1996).
4. INK4b genes, as well as neighbouring 9p21 markers, in sporadic melanoma. Cancer Res., 56, 5023-5032 (1996).
5. GRUIS, N.A. and 12 OTHERS, Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Amer. J. Pathol., 146, 1199-1206 (1995).
6. INK4b is a potential effector of cell-cycle arrest mediated by TGF-β. Nature (Lond.), 371, 257-261 (1994).
7. HEALY, E., REHMAN, I., ANGUS, B. and REES, J.L., Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes, Chromosomes Cancer, 12, 152-156 (1995).
8. INK4 in sporadic melanoma. J. invest. Dermatol., 107, 318-321 (1996).
9. HERBST, R.A., GUTZMER, R., MATIASKE, F., MOMMERT, S., KAPP, A., WEISS, J., ARDEN, K.C. and CAVENEE, W.K., Further evidence for ultraviolet-light induction of CDKN2 (p16INK4) mutations in sporadic melanoma in vivo. J. invest. Dermatol., 108, 950 (1997).
10. HOLLAND, E.A., BEATON, S.C., BECKER, T.M., GRULET, O.M.C., PETERS, B.A., RIZOS, H., KEFFORD, R.F. and MANN, G.J., Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene, 11, 2289-2294 (1995).
11. HULTMAN, T., STÅHL, S., HORNES, E. and UHLEN, M., Direct solid-phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Res., 17, 4937-4946 (1989).
12. HUSSUSSIAN, C.J., STRUEWIMG, J.P., GOLDSTEIN, A.M., HIGGINS, P.A.T., ALLY, D.S., SHEAHAN, M.D., CLARK, W.H., TUCKER, M.A. and DRACOPOLI, N.C., Germline p16 mutations in familial melanoma. Nature Genet., 8, 15-21 (1994).
13. INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, Solar and ultra-violet radiation. IARC monographs on the evaluation of carcinogenic risks to humans, Volume 55, IARC, Lyon (1992).
14. JONASON, A.S., KUNALA, S., PRICE, G.J., RESTIFO, R.J., SPINELLI, H.M., PERSING, J.A., LEFFELL, D.J., TARONE, R.E. and BRASH, D.E., Frequent clones of p55-mutated keratinocytes in normal human skin. Proc. nat. Acad. Sci. (Wash.), 93, 14025-14029 (1996).
15. KAMB, A., GRUIS, N.A., WEAVER-FELDHAUS, J., LIU, Q., HARSHMAN, K., TAVTIGIAN, S.V., STOCKERT, E., DAY, R.S. 3RD., JOHNSON, B.E. and SKOLNICK, M.H., A cell-cycle regulator potentially involved in genesis of many tumour types. Science, 264, 436-440 (1994).
16. KANJILAL, S., STROM, S.S., CLAYMAN, G.L., WEBER, R.S., EL-NAGGAR, A.K., KAPUR, V., CUMMINGS, K.K., HILL, L.A., SPITZ, M.R., KRIPKE, M. and ANANTHASWAMY, H.N., p53 mutations in non-melanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res., 55, 3604-3609 (1995).
17. KOH, J., ENDERS, G.H., DYNLACHT, B.D. and HARLOW, E., Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (Lond.), 375, 506-510 (1995).
18. KOMIYA, A., SUZUKI, H., AIDA, S., YATANI, R. and SHIMAZAKI, J., Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jap. J. Cancer Res., 86, 622-625 (1995).
19. LIU, Q., NEUHAUSEN, S., MCCLURE, M., FRYE, C., WEAVER-FELDHAUS, J., GRUIS, N.A., EDDINGTON, K., ALLALUNIS-TURNER, M.J., SKOLNICK, M.H., FUJIMURA, F.K. and KAMB, A., CDKN2 (MTS1) tumour-suppressor gene mutations in human tumour cell lines. Oncogene, 10, 1061-1067 (1995).
20. MÆLANDSMO, G.M., FLORENES, V.A., HOVIG, E., ØYJORD, T., ENGEBRAATEN, O., HOLM, R., BORRESEN, A.-L. and FODSTAD, Ø., Involvement of pRb/p16/ cdk4/eyclin-D1 pathway in the tumorigenesis of sporadic melanomas. Brit. J. Cancer, 7A 909-916 (1996).
21. OHTA, M., BERD, D., SHIMIZU, M., NAGAI, H., COTTICELLI, M.-G., MASTRANGELO, M., SHIELDS, J.A., SHIELDS, C.L., CROCE, C.M. and HUEBNER, K., Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus on melanoma. Int. J. Cancer, 65, 762-767 (1996).
22. OHTA, M., NAGAI, H., SHIMIZU, M., RASIO, D., BERD, D., MASTRANGELO, M., SINGH, A.D., SHIELDS, J.A., SHIELDS, C.L., CROCE, C.M. and HUEBNER, K., Rarity of somatic and germline mutations of cyclin-dependent kinase-4 inhibitor gene, CDK4I, in melanoma. Cancer Res., 54, 5269-5272 (1994).
23. INK4 in human cancer. Proc. nat. Acad. Sci. (Wash.), 91, 11045-11049 (1994).
24. ORITA, M., IWAHANA, H., KANAZAWA, H., HAVASHI, K. and SEKIYA, T., Detection of polymorphism of human DNA by gel electrophoresis as single-stranded conformational polymorphisms. Proc. nat. Acad. Sci. (Wash.), 86, 2766-2770 (1989).
25. PICCININ, S., DOGLIONI, C., MAESTRO, R., VUKOSAVIJEVIC, T., GASPAROTTO, D., D'ORAZI, C. and BOIOCCHI, M., p16/CDKN2 and CDK gene mutations in sporadic-melanoma development and progression. Int. J. Cancer (Pred. Oncol.), 74, 26-30 (1997).
26. PLATZ, A., RINGBORG, U., LAGERLÖF, B., LUNDQVIST, E., SEVIGNY, P. and INGANÄS, M., Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Brit. J. Cancer, 73, 344-348 (1996).
27. POLLOCK, P.M., YU, F., QIU, L., PARSONS, P.C. and HAYWARD, N.K., Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene, 11, 663-668 (1995).
28. SERRANO, M., HANNON, G.J. and BEACH, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366, 704-707 (1993).
29. INK4A) somatic and germline mutations. Hum. Mutation, 7, 294-303 (1996).
30. UEKI, K., RUBIO, M.-P., RAMESH, V., CORREA, K.M., RUTTER, J.L., VON DEIMLING, A., BUCKLER, A.J., GUSELLA, J.F. and LOUIS, D.N., MTS1/ CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum. mol. Genet., 3, 1841-1845 (1994).
31. INK4 gene in Australian melanoma kindreds. Hum. mol. Genet., 4, 1845-1852 (1996).
32. ink4 in human breast carcinomas. Cancer Res., 54, 5262-5264 (1994).
33. INK4 proteins encoded by tumour-derived alleles. J. biol. Chem., 271, 28734-28737 (1996).